Abacavir News and Research RSS Feed - Abacavir News and Research

Abacavir sulfate, also known as Ziagen or ABC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself.
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. [More]
Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. [More]
European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age. [More]
More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

​The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1). [More]
WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society Conference, include new antiretroviral therapy recommendations for HIV-infected children, and will mean that more children will be on better treatments. [More]

GlaxoSmithKline's HIV/AIDS business joins Medicines Patent Pool

"GlaxoSmithKline's HIV/AIDS drugs business is to share intellectual property rights on children's medicine in a patent pool designed to make treatments more widely available in poor countries," Reuters reports. [More]
Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults. [More]

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan Inc. today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations. [More]
FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

Today, U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg announced the agency has approved or tentatively approved a total of 152 antiretroviral drugs in association with the President's Emergency Plan for AIDS Relief (PEPFAR) to treat those infected with HIV/AIDS in countries that lack the tools needed to fight the AIDS epidemic. [More]
All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS. [More]
Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

On the eve of the XIX International AIDS Conference in Washington, DC, the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, announces a new collaboration with Indian drug manufacturer Cipla to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS. [More]
Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. [More]
Researchers identify mechanism key in drug allergy

Researchers identify mechanism key in drug allergy

Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man. [More]
Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according to a study published online by the journal AIDS, official journal of the International AIDS Society. [More]
Researchers identify new mechanism for drug-related autoimmune reactions

Researchers identify new mechanism for drug-related autoimmune reactions

A team of researchers led by the U.S. Food and Drug Administration has discovered a new mechanism for identifying and understanding drug-related autoimmune reactions. [More]
ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. [More]
Study explores links between antiretroviral prophylaxis, cleft lip and palate

Study explores links between antiretroviral prophylaxis, cleft lip and palate

HIV-positive mothers have been able to guard against transmitting the disease to their babies by taking antiretroviral drugs during pregnancy. Although the drugs prevent children from being born with HIV, they could cause birth defects, such as cleft lip and palate. A new study explores any links between antiretroviral prophylaxis and cleft lip and palate. [More]

WHO approves three Mylan ARV therapies to treat HIV/AIDS

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include: [More]
FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults. [More]